These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1329 related articles for article (PubMed ID: 25131830)

  • 1. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
    Falkenberg KJ; Johnstone RW
    Nat Rev Drug Discov; 2014 Sep; 13(9):673-91. PubMed ID: 25131830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of histone deacetylases in cancer.
    Montezuma D; Henrique RM; Jerónimo C
    Crit Rev Oncog; 2015; 20(1-2):19-34. PubMed ID: 25746102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC11: a rising star in epigenetics.
    Liu SS; Wu F; Jin YM; Chang WQ; Xu TM
    Biomed Pharmacother; 2020 Nov; 131():110607. PubMed ID: 32841898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and emerging HDAC inhibitors for cancer treatment.
    West AC; Johnstone RW
    J Clin Invest; 2014 Jan; 124(1):30-9. PubMed ID: 24382387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
    Vaidya GN; Rana P; Venkatesh A; Chatterjee DR; Contractor D; Satpute DP; Nagpure M; Jain A; Kumar D
    Eur J Med Chem; 2021 Jan; 209():112844. PubMed ID: 33143937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.
    Zhang S; Zhan L; Li X; Yang Z; Luo Y; Zhao H
    Int J Biol Sci; 2021; 17(13):3381-3400. PubMed ID: 34512154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase 10, a potential epigenetic target for therapy.
    Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Niu Z; He W
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 33997894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
    Ranganna K; Selvam C; Shivachar A; Yousefipour Z
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
    Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
    J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
    Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
    Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases and inhibitors in diabetes mellitus and its complications.
    Wang L; Bai Y; Cao Z; Guo Z; Lian Y; Liu P; Zeng Y; Lyu W; Chen Q
    Biomed Pharmacother; 2024 Aug; 177():117010. PubMed ID: 38941890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
    Li Z; Zhu WG
    Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.